Kentaro Tanaka

Assistant Professor

Kyushu University

Japan

Research Interests

Explore related searches

Professors in Japan Professors in Cancer Research Cancer Research professors in Japan

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Kentaro Tanaka is an Assistant Professor at Kyushu University in Japan. His research primarily focuses on advanced non-small cell lung cancer and cancer cachexia, as evidenced by his involvement in multiple clinical studies comparing various treatment regimens. He has contributed significantly to understanding the prognostic factors affecting cancer patient outcomes, particularly with anti-PD-1 therapies. His recent publications reflect his commitment to advancing cancer treatment through rigorous clinical research.

Articles (10)

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (5)

Tateaki Naito

Clinical Professor

St. Luke's International University

JAPAN

View details

Hiroyuki Inoue

Associate Professor

Fukuoka University

JAPAN

View details

Yuki Ikematsu

JAPAN

View details

Shogo Nomura

Project Lecturer

University of Tokyo

JAPAN

View details

Katsuyuki Kiura

Okayama University Hospital

JAPAN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Kentaro Tanaka

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

A Multicenter, Randomized Phase III Study Comparing Platinum Combination Chemotherapy Plus Pembrolizumab With Platinum Combination Chemotherapy Plus Nivolumab and Ipilimumab for Treatment-Naive Advanced Non–Small Cell Lung Cancer Without Driver Gene Alterations: JCOG2007 (NIPPON Study)

A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in patients with cancer cachexia and low body mass index

A propensity score-matched analysis of the impact of statin therapy on the outcomes of patients with non-small-cell lung cancer receiving anti-PD-1 monotherapy: a multicenter retrospective study

Assessment of the albumin-bilirubin grade as a prognostic factor in patients with non-small-cell lung cancer receiving anti-PD-1-based therapy

Corrigendum to ‘Gefitinib induction followed by chemoradiotherapy in EGFR-mutant, locally advanced non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study’: [ESMO Open Volume 6, Issue 4, August 2021, 100191] (ESMO Open (2021) 6(4), (S2059702921001526), (10.1016/j.esmoop.2021.100191))

Immunostimulatory oncolytic activity of coxsackievirus A11 in human malignant pleural mesothelioma

Reliability, validity, and responsiveness of the Japanese version of the EORTC QLQ-ELD14 in evaluating the health-related quality of life of elderly patients with cancer

A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non–Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801)

A Phase II Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis From NSCLC: Results for the T790M Cohort of the OCEAN Study (LOGIK1603/WJOG9116L)

A case of primary hepatic leiomyosarcoma treated with multi-line chemotherapy

Collaborators (5)

Tateaki Naito

Hiroyuki Inoue

Yuki Ikematsu

Shogo Nomura

Katsuyuki Kiura

Make your next move.